Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Amortization of Deferred Charges: 2020-2024

Historic Amortization of Deferred Charges for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $3.0 million.

  • Xeris Biopharma Holdings' Amortization of Deferred Charges changed negligibly% to $800,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 20.18%. This contributed to the annual value of $3.0 million for FY2024, which is 36.37% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Amortization of Deferred Charges of $3.0 million as of FY2024, which was up 36.37% from $2.2 million recorded in FY2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Amortization of Deferred Charges peaked at $3.0 million during FY2024, and registered a low of $980,000 during FY2020.
  • In the last 3 years, Xeris Biopharma Holdings' Amortization of Deferred Charges had a median value of $2.2 million in 2023 and averaged $2.3 million.
  • Data for Xeris Biopharma Holdings' Amortization of Deferred Charges shows a peak YoY soared of 60.00% (in 2022) over the last 5 years.
  • Over the past 5 years, Xeris Biopharma Holdings' Amortization of Deferred Charges (Yearly) stood at $980,000 in 2020, then increased by 2.04% to $1.0 million in 2021, then surged by 60.00% to $1.6 million in 2022, then skyrocketed by 37.81% to $2.2 million in 2023, then soared by 36.37% to $3.0 million in 2024.